Journal
JACC-CARDIOVASCULAR INTERVENTIONS
Volume 11, Issue 7, Pages 615-625Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcin.2017.10.052
Keywords
chronic total occlusion; percutaneous coronary intervention; stable coronary artery disease
Categories
Funding
- Asahi Intecc
- ACIST Medical Systems
- Gilead
- The Medicines Company
- Boston Scientific
- Merck
- Osprey
- Biosensors
Ask authors/readers for more resources
Percutaneous coronary intervention (PCI) for chronic total occlusions (CTOs) has been rapidly evolving during recent years. With improvement in equipment and techniques, high success rates can be achieved at experienced centers, although overall success rates remain low. Prospective, randomized-controlled data regarding optimal use and indications for CTO PCI remain limited. CTO PCI should be performed when the anticipated benefit exceeds the potential risk. New high-quality studies of the clinical outcomes and techniques of CTO PCI are needed, as is the expansion of expert centers and operators that can achieve excellent clinical outcomes in this challenging patient and lesion subgroup. In the current review the authors summarize the latest publications in CTO PCI and provide an overview of the current state of the field. (c) 2018 the American College of Cardiology Foundation. Published by Elsevier. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available